Exelixis Posts Preliminary '25 Results, Issues '26 Outlook

Key Takeaways EXEL reported preliminary 2025 revenues of approximately $2.32B and issued 2026 guidance of $2.525 -$2.625B.EXEL's Cabometyx led RCC and expanded into pNET and epNET in 2025, supporting sales growth into 2026.EXEL filed an NDA for zanzalintinib in metastatic CRC and is preparing for its first potential launch.Exelixis, Inc. (EXEL) reported preliminary, unaudited financial results for fiscal year 2025, issued financial guidance for fiscal 2026, and provided a business update.However, the stock ...